Slim Weight Loss Clinic（Kailua, HI）

Slim Weight Loss Clinic in Kailua, Hawaii operates under the medical direction of Dr. Gary T. Marshall, MD, FACS, a board-certified surgeon who applies surgical precision to non-surgical weight management protocols. The clinic focuses exclusively on evidence-based pharmacotherapy for obesity and metabolic health, serving patients throughout Oahu’s windward coast who require medical intervention beyond diet and exercise alone. Dr. Marshall’s background in bariatric surgery informs his approach to peptide-based weight loss, allowing him to identify candidates who benefit most from GLP-1 receptor agonist therapy and to monitor for contraindications that general practitioners might overlook.

The clinic’s formulary centers on three FDA-approved GLP-1 medications: semaglutide, tirzepatide, and liraglutide, each selected based on patient-specific factors including BMI, comorbidities, insurance coverage, and tolerance profiles. Semaglutide is administered as a once-weekly subcutaneous injection, typically initiated at 0.25 mg and titrated over sixteen weeks to therapeutic doses of 1.7-2.4 mg depending on response and side effect profile. Tirzepatide, a dual GIP/GLP-1 receptor agonist, follows a similar weekly injection schedule with dosing that begins at 2.5 mg and may escalate to 10-15 mg for patients requiring greater glycemic control or appetite suppression. Liraglutide serves as a daily injection alternative for patients who prefer more frequent dosing with shorter half-life kinetics, starting at 0.6 mg and advancing to 3.0 mg maintenance. Dr. Marshall adjusts medication selection based on individual metabolic panels, A1C levels in diabetic patients, and cardiovascular risk stratification.

Patients at Slim Weight Loss Clinic undergo comprehensive metabolic assessment before initiating peptide therapy, including thyroid function panels, lipid profiles, liver enzymes, and renal function tests to establish baseline organ health. Dr. Marshall conducts all initial consultations in person at the Kailua office, performing physical examinations that include body composition analysis and review of prior weight loss attempts, surgical history, and current medications that may interact with GLP-1 agonists. His surgical training proves particularly valuable when evaluating patients with previous bariatric procedures or those considering surgery as a future option, allowing him to position peptide therapy appropriately within a broader treatment algorithm. The clinic does not offer telehealth services, requiring patients to attend regular follow-up appointments for medication adjustments, side effect management, and monitoring of weight loss velocity to ensure loss remains within safe parameters of 1-2 pounds per week.

The treatment protocol at Slim Weight Loss Clinic extends beyond prescription management to include nutritional counseling tailored to the appetite suppression effects of GLP-1 medications, which often reduce caloric intake to levels requiring strategic meal planning to maintain adequate protein and micronutrient consumption. Dr. Marshall addresses common side effects including nausea, constipation, and gastric delayed emptying through dosing modifications and supportive medications rather than discontinuation, recognizing that transient gastrointestinal symptoms typically resolve within 4-6 weeks of stable dosing. Patients with type 2 diabetes receive coordinated care that accounts for the glucose-lowering effects of these peptides, often allowing reduction or elimination of sulfonylureas, insulin, or other diabetic medications as glycemic control improves. The clinic maintains a conservative approach to patient selection, declining to treat individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 due to contraindications identified in peptide safety data.

Slim Weight Loss Clinic’s location in Kailua provides accessible care for residents of windward Oahu communities including Kaneohe, Waimanalo, and Lanikai, with office hours structured to accommodate working professionals who require early morning or late afternoon appointments. Dr. Marshall’s practice philosophy emphasizes that GLP-1 peptides function as tools for appetite regulation and metabolic optimization rather than standalone solutions, requiring patients to engage in concurrent lifestyle modification for sustained results. The clinic does not accept insurance directly but provides itemized superbills for patients to submit for out-of-network reimbursement, with medication costs varying based on manufacturer, dosage, and whether patients qualify for savings programs. This cash-pay structure allows Dr. Marshall to spend extended time with patients during follow-up visits, typically 20-30 minutes, rather than the abbreviated appointments common in insurance-driven practices.